MEMPHIS, Tenn. --(Business Wire)--
Meridian Life Science, Inc. (MLS), Memphis, Tennessee, announces additional investments into facilities, equipment and infrastructure to support R&D and contract manufacturing activities. Increasing demand for contract R&D and biological reagent manufacturing has resulted in a comprehensive facilities plan that will allow MLS to meet customer needs and position the organization for further growth in contract biologics manufacturing. This facility expansion, follows the recent investment in 2009 which resulted in an additional cleanroom biomanufacturing suite, a sterility suite and a pilot production laboratory.
The plan involves the consolidation of all current R&D laboratories and the construction of a centralized R&D center for excellence that will be used to develop new products and to provide R&D support for contract manufacturing and custom biologics development. MLS will utilize other areas of the facility for the construction of up to five contract manufacturing, cell culture, and purification laboratories designed to support increased demand for contract manufacturing of monoclonal antibodies, viral antigens and recombinant proteins. Both the R&D center and the contract manufacturing laboratories will be outfitted with state of the art equipment for cell culture and protein purification. Included in the expansion plan is the construction of a molecular biology laboratory with RT-PCR (News - Alert) capabilitiesand an expanded QC lab for testing incoming and outgoing materials.
These improvements will also be used to provide additional capabilities for pilot scale and process development activities in support of our cGMP biopharmaceutical manufacturing activities which include cell and virus banking, live attenuated or recombinant viral vaccines, viral challenge materials, virus like particle vaccines, vectored gene therapy products, and recombinant proteins made in insect cell culture. The expansion will further enhance our capabilities in upstream and downstream process development and optimization, scale-up, formulations, assay development, viral quantitation, and clinical fill and finish.
MLS continues to see strong interest in the sector for contract R&D, monoclonal antibody production, recombinant protein production, and Phase I/II clinical material production. Dr. Lourdes Weltzien, General Manager for the MLS Memphis Facility commented, "This recent round of expansion is necessary to provide the level and quality of contract manufacturing support our customers expect and require for their custom and critical biological reagents. We are excited and committed to increasing our capacity to service our customers, who can benefit from our core competence in cell culture, protein production and purification. This recent expansion reaffirms our commitment as a leader in contract R&D and biologics manufacturing."
ABOUT MERIDIAN LIFE SCIENCE:
Meridian Life Science, Inc. provides contract R&D, process development, and manufacturing of critical assay reagents, antigens, antibodies, and contract biological R&D and manufacturing services to the research, diagnostic, and biopharmaceutical markets. MLS also provides clinical cGMP biomanufacturing of vaccines, viral challenge materials, gene therapies, virus-like particles, and recombinant proteins at its contract biopharmaceutical manufacturing facility in Memphis, TN. With 25 years of cell culture experience, protein expression, purification, assay development and quality, MLS has become a leader and trusted partner for the supply of critical reagents and clinical materials. MLS services its customers from three primary manufacturing operations in Memphis, Tennessee; Saco, Maine; and Boca Raton, Florida. The Company's shares are traded through NASDAQ's Global Select Market, symbol VIVO. Meridian's website address is www.meridianlifescience.com.